As of June 20, 2025, Regeneron Pharmaceuticals Inc (REGN) reports a Gross Margin of 87.01%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Regeneron Pharmaceuticals Inc's Gross Margin
Over recent years, Regeneron Pharmaceuticals Inc's Gross Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2024-12-31 | 87.01% |
| 2023-12-31 | 86.94% |
| 2022-12-31 | 87.18% |
| 2021-12-31 | 84.83% |
| 2020-12-31 | 86.82% |
This slight downward trend highlights how Regeneron Pharmaceuticals Inc manages its operational efficiency and pricing power over time.
Comparing Regeneron Pharmaceuticals Inc's Gross Margin to Peers
To better understand Regeneron Pharmaceuticals Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Regeneron Pharmaceuticals Inc (REGN) | 87.01% |
| Allogene Therapeutics Inc (ALLO) | 7775.20% |
| Fate Therapeutics Inc (FATE) | 7775.20% |
| Intellia Therapeutics Inc (NTLA) | 7775.20% |
| Kodiak Sciences Inc (KOD) | 7775.20% |
| Sana Biotechnology Inc (SANA) | 7775.20% |
Compared to its competitors, Regeneron Pharmaceuticals Inc's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.